Benitec Biopharma Inc. (BNTC)
| Previous close | 0.2076 |
| Open | 0.2097 |
| Bid | 0.2230 x 2900 |
| Ask | 0.2282 x 800 |
| Day's range | 0.2097 - 0.2350 |
| 52-week range | 0.1310 - 2.4000 |
| Volume | |
| Avg. volume | 312,318 |
| Market cap | 6.377M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.8000 |
| Earnings date | 15 May 2023 - 19 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
- GlobeNewswire
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
First subject enrolled into the OPMD clinical development programHAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q
- GlobeNewswire
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History (NH) S
- GlobeNewswire
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update
HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S.
